Decoy Therapeutics Inc. entered into a Securities Purchase Agreement on June 26, 2026, for a private placement of 592,217 shares of common stock at $5.91 per share, expected to close on June 29, 2026. The transaction includes milestone-based Series A, B, and C warrants that could provide up to $17.5 million in additional gross proceeds upon meeting specific clinical trial milestones. Decoy Therapeutics Inc. is a biotechnology company focused on developing therapeutic assets into clinical trials.